Please login to the form below

Not currently logged in
Email:
Password:

Bayer seeks ACS approval for Xarelto

Bayer has said it intends to file Xarelto (rivaroxaban) for marketing approval in the treatment of patients with acute coronary syndrome (ACS)

Bayer has said it intends to file its blood thinner Xarelto (rivaroxaban) for marketing approval in the treatment of patients with acute coronary syndrome (ACS) by the end of 2011.

The announcement comes after a phase III trial that demonstrated that Xarelto plus standard therapy significantly reduced the rate of events for the study's primary endpoint of cardiovascular death, myocardial infarction and stroke in patients with ACS.

However, Xarelto also demonstrated a significant increase in major bleeding events not associated with coronary artery bypass graft surgery – the primary safety endpoint of the trial.

Xarelto, which Bayer is co-developing with Johnson & Johnson, is already approved for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.

The US Food and Drug Administration (FDA) recently recommended the drug for use in stroke prevention in patients with the heart condition nonvalvular atrial fibrillation.

3rd October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics